Related Experiment Video
Updated: Dec 15, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum
Laura M Smeaton1, Emma M Kileel2, Beatriz Grinsztejn3
1Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
None:
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.
Related Concept Videos
The Stanford Prison Experiment
Ethnic Identity within a Larger Culture
Dissociative Identity Disorder
Stereotypes, Prejudice, and Discrimination
Borderline Personality Disorder
Genetic and Environmental Contributions
Borderline Personality...
Repressed Memory

